MEDICAL DEVICES, TECHNOLOGIES, EQUIPMENT, SUPPLIES
1 min.Read

NIOX® Group Celebrates 25 Years of Innovation in FeNO Testing for Asthma

NIOX® Group (NIOX®) proudly announces the celebration of the 25th anniversary of its cutting-edge asthma diagnosis and management technology. Since its foundation, the company has worked to help improve asthma care with its ground-breaking FeNO testing devices. With almost 50 million tests performed worldwide, NIOX® continues to lead the development of FeNO for patient care.

NIOX® technology, developed by the visionary scientists who discovered the value of FeNO (fractional exhaled nitric oxide) testing in asthma, has played a pivotal role in helping to transform the way asthma can be diagnosed and managed.1-4 FeNO testing has become an important tool for healthcare professionals in assessing airway inflammation and guiding treatment decisions.4-7 The milestone achievement of nearly 50 million FeNO tests performed using NIOX® technology is testament to its widespread adoption and impact on patient health.

In recognition of its commitment to innovation, NIOX® has received prestigious accolades. In 2021, the company was honoured with the award for Most Innovative Asthma Management Technology, highlighting its pioneering contributions to the field. In 2022, NIOX® was named Best FeNO Testing Provider and acknowledged as Leaders in FeNO Testing Technology Development later that same year. These awards not only reflect the dedication of the entire team at NIOX® but also validate the confidence placed in the company by healthcare professionals worldwide.

NIOX® Executive Chairman, Ian Johnson, said: “On this momentous occasion, we would like to express our sincere gratitude to our colleagues and to our customers for their continued support. The success of the past 25 years would not have been possible without the dedication and hard work of the talented individuals who have been part of the NIOX® family. Their commitment to advancing asthma care has been instrumental in shaping the company’s success. Thank you all.”

NIOX® remains committed to driving innovation in asthma management and improving the lives of patients. As the company looks to the future, it continues to invest in research and development to further enhance NIOX® technology. With a continued focus on delivering market-leading products and unparalleled support to healthcare professionals, NIOX® aims to further solidify its position as a global leader in FeNO testing.

Watch the fascinating story of FeNO testing in a new short film:

SourceNIOX® Group

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

0
Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

0
Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

0
Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

0
The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

0
“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

About us

Medical Device News Magazine

Welcome to Medical Device News Magazine, a digital publication providing up to the minute medical device news and biotechnology news.

Need to know more?

Contact us

Navigation

Florida, New York
United States
Phone Number: 1.561.316.3330